Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications.
- Hope TA 1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, 505 Parnassus Ave, San Francisco, CA 94143-0628.
- Afshar-Oromieh A 4 Department of Nuclear Medicine, Bern University Hospital, Bern, Switzerland.
- Eiber M 6 Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University of Munich, Germany.
- Emmett L 7 Department of Diagnostic Imaging, St. Vincent's Public Hospital, Sydney, Australia.
- Fendler WP 10 Klinik für Nuklearmedizin, Universitätsklinikum, Essen, Germany.
- Lawhn-Heath C 1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, 505 Parnassus Ave, San Francisco, CA 94143-0628.
- Rowe SP 11 The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD.
- 2018-06-28
Published in:
- AJR. American journal of roentgenology. - 2018
PET
PET/MRI
prostate cancer
prostate-specific membrane antigen
Biomarkers, Tumor
Humans
Magnetic Resonance Imaging
Male
Multimodal Imaging
Neoplasm Staging
Patient Selection
Positron Emission Tomography Computed Tomography
Prostate-Specific Antigen
Prostatic Neoplasms
English
OBJECTIVE
The purpose of this article is to describe the large number of radiotracers being evaluated for prostate-specific membrane antigen (PSMA) PET, which is becoming a central tool in the staging of prostate cancer.
CONCLUSION
PSMA PET is a highly promising modality for the staging of prostate cancer because of its higher detection rate compared with that of conventional imaging. Both PET/CT and PET/MRI offer benefits with PSMA radiotracers, and PSMA PET findings frequently lead to changes in management. It is imperative that subsequent treatment changes be evaluated to show improved outcomes. PSMA PET also has potential applications, including patient selection for PSMA-based radioligand therapy and evaluation of treatment response.
The purpose of this article is to describe the large number of radiotracers being evaluated for prostate-specific membrane antigen (PSMA) PET, which is becoming a central tool in the staging of prostate cancer.
CONCLUSION
PSMA PET is a highly promising modality for the staging of prostate cancer because of its higher detection rate compared with that of conventional imaging. Both PET/CT and PET/MRI offer benefits with PSMA radiotracers, and PSMA PET findings frequently lead to changes in management. It is imperative that subsequent treatment changes be evaluated to show improved outcomes. PSMA PET also has potential applications, including patient selection for PSMA-based radioligand therapy and evaluation of treatment response.
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.2214/AJR.18.19957
- PMID 29949419
- Persistent URL
- https://folia.unifr.ch/global/documents/167133
Statistics
Document views: 28
File downloads:
- fulltext.pdf: 0